Brain Development Research Program

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jan 2025 to Jan 2027v22
  2. 2 versions Re-verified since Aug 3, 2022, no change to tracked fieldsv20-v21
  3. Publications: 13 to 19
    • Study description expanded, about 2 words
    v19
  4. Primary and study completion dates: Jan 2020 to Jan 2025v18
  5. Re-verified, no change to tracked fieldsv17
Show 15 earlier versionsHide 15 earlier versions
  1. Primary and study completion dates: Jan 2018 to Jan 2020v16
  2. 2 versions Re-verified since Dec 2, 2015, no change to tracked fieldsv14-v15
  3. Primary and study completion dates: Jan 2018
    • Study description expanded, about 6 words
    v13
  4. 2 versions Re-verified since Nov 13, 2012, no change to tracked fieldsv11-v12
  5. Enrollment target: 500 to 2000v10
  6. Collaborators: 3 to 2
    • Publications: 9 to 13
    v9
  7. Publications: 1 to 9v8
  8. Study description shortened, about 9 wordsv7 Show 4 more changesShow less
    • Site contact updated
    • Collaborators: 1 to 3
    • Study title shortened, about 6 words
    • Eligibility criteria expanded, about 4 words
  9. Study description revisedv6
  10. Study completion date: Sep 2006 to not stated
    • Study description shortened, about 2 words
    v5
  11. Eligibility criteria revised
    • Study description expanded, about 7 words
    • Study title revised
    v4
  12. Study completion date: Jul 2005 to Sep 2006v3
  13. Study description expanded, about 4 words
    • Study title expanded, about 3 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dr. Elliott Sherr and his collaborators at University of California, San Francisco (UCSF) are studying the genetic causes of disorders of cognition and epilepsy, in particular disorders of brain development that affect the corpus callosum, such as Aicardi syndrome, as well as two additional brain malformations, polymicrogyria and Dandy-Walker malformation. The goal of the investigators' research is to use a better understanding of the underlying genetic causes as a foundation to develop better treatments for these groups of patients.
Trial Details
NCT Number NCT00305305
Lead Sponsor University of California, San Francisco
Collaborators: University of Washington, California Institute of Technology
Conditions
(from sponsor)		 Brain Disorders, Aicardi Syndrome
Related terms Agenesis of Corpus Callosum, Aicardi Syndrome, Autistic Disorder, Brain Diseases, Epilepsy, Intellectual Disability, Polymicrogyria
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov